PAZOPANIB

Generic	Brand	HICL	GCN	Exception/Other
PAZOPANIB	VOTRIENT	36709		

This drug requires a written request for prior authorization.

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC)?

   If yes, **approve for 12 months by HICL with a quantity limit of #4 tablets per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced soft tissue sarcoma (STS) and meets the following criteria?
   The patient had a trial of or contraindication to chemotherapy (e.g., anthracycline treatment),
   The patient does not have a diagnosis of adipocytic soft tissue sarcoma (STS) or gastrointestinal stromal tumors (GIST)

   If yes, **approve for 12 months by HICL with a quantity limit of #4 tablets per day.**
   If no, do not approve.
   DENIAL TEXT: The guideline named **PAZOPANIB (Votrient)** requires a diagnosis of advanced renal cell carcinoma (RCC) or advanced soft tissue sarcoma (STS). In addition, the following criteria must also be met.
   For patients with a diagnosis of advanced soft tissue sarcoma (STS), approval requires all of the following:
   The patient had a trial of or contraindication to chemotherapy (e.g., anthracycline treatment)
   The patient does not have a diagnosis of adipocytic soft tissue sarcoma (STS) or gastrointestinal stromal tumors (GIST)

RATIONALE
Ensure appropriate utilization of pazopanib based on FDA approved indication and dosing.

FDA APPROVED INDICATIONS
Votrient is indicated for the treatment of patients with:
Advanced renal cell carcinoma (RCC)
Advanced soft tissue sarcoma (STS) who have received prior chemotherapy

Limitation of use: the efficacy of Votrient for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors (GIST) has not been demonstrated.

CONTINUED ON NEXT PAGE

PAZOPANIB

FDA APPROVED INDICATIONS (CONTINUED)

DOSAGE AND ADMINISTRATION

The recommended starting dose of Votrient is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). The dose of Votrient should not exceed 800 mg.

Do not crush tablets due to the potential for increased rate of absorption, which may affect systemic exposure. If a dose is missed, it should not be taken if it less than 12 hours until the next dose.

REFERENCES

Votrient [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. August 2016.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 10/01/16
Created: 05/11
Client Approval: 09/16
P&T Approval: 08/16